Aditya Bardia
阿迪蒂亚·巴尔迪亚
MD, MPH
Director of Breast Cancer Research Program乳腺癌研究项目主任
👥Biography 个人简介
Aditya Bardia is a global leader in antibody-drug conjugates (ADCs) for breast cancer, most notably sacituzumab govitecan. His translational work at MGH and now UCLA has driven FDA approvals that have redefined treatment for metastatic TNBC and HR+ breast cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Sacituzumab Govitecan Development
Played a leading role in ASCENT trial, establishing sacituzumab govitecan as standard-of-care for relapsed/refractory metastatic TNBC with significant survival benefit.
ADC Landscape in Breast Cancer
Advanced multiple ADC programs across breast cancer subtypes, defining mechanisms of resistance and combination strategies to optimize ADC efficacy.
Representative Works 代表性著作
Sacituzumab govitecan in metastatic TNBC (ASCENT trial)
New England Journal of Medicine (2021)
Pivotal phase 3 trial demonstrating superior PFS and OS with sacituzumab govitecan vs chemotherapy in relapsed TNBC.
Trodelvy in HR+/HER2- metastatic breast cancer (TROPiCS-02)
Journal of Clinical Oncology (2023)
Established sacituzumab govitecan benefit in pretreated HR+ metastatic breast cancer, expanding ADC indications.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 阿迪蒂亚·巴尔迪亚 的研究动态
Follow Aditya Bardia's research updates
留下邮箱，当我们发布与 Aditya Bardia（UCLA Jonsson Comprehensive Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment